A5053302725- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Vitamin C and Antioxidants Research
- Polyomavirus and related diseases
- Anesthesia and Sedative Agents
- Anesthesia and Neurotoxicity Research
- Cytomegalovirus and herpesvirus research
- Monoclonal and Polyclonal Antibodies Research
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2021-2024
Charité - Universitätsmedizin Berlin
2016-2023
Humboldt-Universität zu Berlin
2019-2021
Freie Universität Berlin
2019-2021
Vivantes Klinikum
2019
Abstract Cellular senescence is a stress-inducible state switch relevant in aging, tumorigenesis and cancer therapy. Beyond lasting arrest, senescent cells are characterized by profound chromatin remodeling transcriptional reprogramming. We show here myeloid-skewed aberrant lineage plasticity its immunological ramifications therapy-induced (TIS) of primary human murine B-cell lymphoma. find myeloid transcription factor (TF) networks, specifically AP-1-, C/EBPβ- PU.1-governed programs,...
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61–80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ≥2). Patients receive standard chemotherapy (CHOP) plus immunotherapy (Rituximab), biological agent (the proteasome inhibitor Bortezomib) signaling Bruton's Tyrosine Kinase-targeting therapeutic Ibrutinib). Using all-comers approach, but...
Diffuse large-cell B-cell lymphoma (DLBCL) is the most common lymphoid malignancy. About 30–40% of patients will not be cured by standard Rituximab (R)-CHOP-like immune-chemotherapy, and many them experience relapse eventually succumb to their disease. Enhancing first-line efficacy in at higher risk, among elderly, key improve long-term outcomes. Numerous attempts combine R-CHOP with targeted agents failed large randomized phase III trials. The addition Ibrutinib enhanced survival younger...
Introduction: Most recent phase III trials investigating single targeted treatment additions to R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL) failed, at least part, due the high heterogeneity of this disease. While re-analyses negative (e.g. PHOENIX ± ibrutinib or REMoDL-B bortezomib) unveiled molecular subgroups that strongly benefitted, we pursued our explorative single-arm open-label I/II ImbruVeRCHOP (ibrutinib + bortezomib R-CHOP) investigator-initiated study (IIS) a...
Introduction: Irrespective of its genomic B-cell origin, classical Hodgkin's lymphoma (cHL) is characterized by the virtual lack gene products whose expression constitutes phenotype. Epigenetic repression B-cell-specific genes was previously postulated to contribute lost phenotype in cHL. Restoration may not only revert a hallmark cHL but provide new Achilles' heel sensitizing clinically established antibody therapies targeting surface receptors as well small compounds interfering with...
Abstract Lymphomas represent a very heterogeneous group of hematologic malignancies and pose an important challenge in the clinical routine. They frequently develop resistance to treatment with standard-of-care (SoC) drugs have high incidence disease recurrence. Recent progress molecular throughput profiling has helped identify genetic drivers subtypes diffuse large B-cell lymphomas (DLBCL). Further target validation drug development projects are highly dependent on corresponding preclinical...
Lymphomas represent a very heterogeneous group of hematologic malignancies and pose an important challenge in the clinical routine. They frequently develop resistance to treatment with standard-of-care (SoC) drugs have high incidence disease recurrence.Recent progress molecular throughput profiling has helped identify genetic drivers subtypes diffuse large B-cell lymphomas (DLBCL). Further target validation drug development projects are highly dependent on corresponding preclinical models...
Abstract Non-Hodgkin lymphomas (NHL) are lymphoid malignant neoplasms that represent a very heterogeneous group and still pose an important clinical challenge. In particular, the frequent development of resistance to treatment with standard-of-care (SoC) drugs is associated high incidence disease recurrence. Recent progress in molecular high-throughput profiling has helped identify genetic drivers for many subtypes B-cell as well T-cell lymphomas. Target validation drug depend on...